SCHEMBL2155476

SCHEMBL2155476

CCCCCC#CC(CS(=O)(=O)N1CCCN(c2ccc(OCC)cc2)CC1)NC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
MAPT P10636 5/20 0.39
KMT2A Q03164 5/20 0.39
HSD17B10 Q99714 2/20 0.39
ALDH1A1 P00352 2/20 0.39
ALOX15 P16050 2/20 0.39
ATM Q13315 1/20 0.38
LMNA P02545 3/20 0.38
NPSR1 Q6W5P4 2/20 0.37
MEN1 O00255 4/20 0.36
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
KDM4E B2RXH2 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
APP P05067 1/20 0.35
GAA P10253 1/20 0.35
ALOX12 P18054 1/20 0.35
MAPK1 P28482 1/20 0.35
SNCA P37840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154976 0.97 POLB (0.44) POLBMAPTKMT2AHSD17B10ALDH1A1
SCHEMBL2156134 0.91 POLB (0.42) POLBMAPTKMT2AHSD17B10ALDH1A1
SCHEMBL2155368 0.88 MAPT (0.42) POLBMAPTALDH1A1ATMLMNA
SCHEMBL2155686 0.87 POLB (0.44) POLBMAPTKMT2AHSD17B10ALDH1A1
SCHEMBL2155145 0.85 KDM4E (0.40) POLBMAPTKMT2AMEN1KDM4E
SCHEMBL2155117 0.85 CYP3A4 (0.46) POLBKMT2AALDH1A1LMNANPSR1
SCHEMBL2156547 0.83 TP53 (0.43) POLBMAPTLMNAKDM4E
SCHEMBL2156665 0.82 CYP3A4 (0.47) POLBKMT2AALDH1A1LMNANPSR1
SCHEMBL2155252 0.82 POLB (0.38) POLBMAPTKMT2AHSD17B10ALDH1A1
SCHEMBL2155970 0.82 ATM (0.46) MAPTKMT2AALDH1A1ATMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 EP claimed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US claimed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 US disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof GLS2, SRM, GLS POLB 4343/4885MAPT 4423/4885KMT2A 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.